{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:11:48Z","timestamp":1772115108651,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T00:00:00Z","timestamp":1451692800000},"content-version":"vor","delay-in-days":1646,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gaceta Sanitaria"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.gaceta.2011.03.006","type":"journal-article","created":{"date-parts":[[2011,6,19]],"date-time":"2011-06-19T12:14:06Z","timestamp":1308485646000},"page":"267-273","source":"Crossref","is-referenced-by-count":14,"title":["An\u00e1lisis de coste-efectividad de la vacunaci\u00f3n antineumoc\u00f3cica en Espa\u00f1a"],"prefix":"10.1016","volume":"25","author":[{"given":"Ra\u00fal","family":"Morano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferr\u00e1n","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Brosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel P\u00e9rez","family":"Escolano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gaceta.2011.03.006_bib0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1695-4033(04)78232-6","article-title":"Epidemiolog\u00eda e impacto de la otitis media aguda en la Comunidad Valenciana","volume":"60","author":"Garc\u00e9s-S\u00e1nchez","year":"2004","journal-title":"An Pediatr"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0010","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0015","series-title":"48th Annual Meeting of the Infectious Diseases Society of America","article-title":"Is non-typeable Haemophilus influenzae (NTHi) a dominant pathogen in recurrent and treatment failure acute otitis media (AOM) episodes in young Spanish children?","author":"Pumarola","year":"2010"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0020","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/S0140-6736(06)68304-9","article-title":"Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study","volume":"367","author":"Prymula","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0025","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1016\/S0264-410X(03)00361-X","article-title":"Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada","volume":"21","author":"De Wals","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0030","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.clinthera.2009.10.014","article-title":"Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model","volume":"31","author":"De Wals","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","article-title":"Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias","volume":"24","author":"L\u00f3pez Bastida","year":"2010","journal-title":"Gac Sanit"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0040","unstructured":"Instituto Nacional de Estad\u00edstica. Poblaci\u00f3n 2008. Disponible en: www.ine.es."},{"key":"10.1016\/j.gaceta.2011.03.006_bib0045","first-page":"159","article-title":"Evoluci\u00f3n de los serotipos de neumococo a lo largo de tres d\u00e9cadas","volume":"49","author":"Fenoll","year":"2009","journal-title":"Bol Pediatr"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0050","unstructured":"Conjunto M\u00ednimo B\u00e1sico de Datos al alta hospitalaria 2008. Disponible en: www.msps.es."},{"key":"10.1016\/j.gaceta.2011.03.006_bib0055","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/01.inf.0000148233.57296.90","article-title":"Haemophilus influenzae: a significant pathogen in acute otitis media","volume":"23","author":"Leibovitz","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0060","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.278.11.925","article-title":"Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988","volume":"278","author":"McIntyre","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0065","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM199012133232402","article-title":"Seizures and other neurologic sequelae of bacterial meningitis in children","volume":"323","author":"Pomeroy","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0070","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1164\/ajrccm.165.5.2105110","article-title":"Pneumococcal meningitis in the intensive care unit: prognostic factors of clinical outcome in a series of 80 cases","volume":"165","author":"Auburtin","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0075","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/brain\/awg113","article-title":"Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases","volume":"126","author":"Kastenbauer","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0080","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(06)69637-2","article-title":"Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study","volume":"368","author":"Whitney","year":"2006","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.gaceta.2011.03.006_bib0085","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0264-410X(00)00284-X","article-title":"Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente","volume":"19","author":"Black","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0090","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3201\/eid1409.071094","article-title":"Pediatric parapneumonic empyema, Spain","volume":"14","author":"Obando","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0095","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/00006454-200211000-00007","article-title":"Multinational study of pneumococcal serotypes causing acute otitis media in children","volume":"21","author":"Hausdorff","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM200102083440602","article-title":"Efficacy of a pneumococcal conjugate vaccine against acute otitis media","volume":"344","author":"Eskola","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0105","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/00006454-200209000-00005","article-title":"Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia","volume":"21","author":"Black","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0110","unstructured":"Consejo General del Colegio Oficial de Farmac\u00e9uticos (CGCOF) 2010. Disponible en: www.portalfarma.com."},{"key":"10.1016\/j.gaceta.2011.03.006_bib0115","unstructured":"Gisbert R, Brosa M. Base de datos de costes sanitarios eSALUD. Barcelona: OblikueConsulting, S.L. 2010. Disponible en: www.oblikue.com\/bddcostes."},{"key":"10.1016\/j.gaceta.2011.03.006_bib0120","unstructured":"Health Survey for England, 1996. (Consultado el 5\/11\/2007.) Disponible en: http:\/\/www.archive.official-documents.co.uk\/document\/doh\/survey96\/tab5-29.htm."},{"key":"10.1016\/j.gaceta.2011.03.006_bib0125","first-page":"43","article-title":"Parents\u2019 utilities for outcomes of occult bacteraemia","volume":"154","author":"Bennett","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0130","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2004.05.003","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales","volume":"22","author":"Melegaro","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1155\/2007\/713576","article-title":"The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine","volume":"18","author":"Morrow","year":"2007","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0140","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/archotol.125.11.1214","article-title":"Cost-utility of the cochlear implant in adults: a meta-analysis","volume":"125","author":"Cheng","year":"1999","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0145","first-page":"485","article-title":"Cost-utility analysis of patient care in children with meningeal signs","volume":"18","author":"Oostenbrink","year":"2002","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0150","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","article-title":"Handling uncertainty in cost-effectiveness models","volume":"17","author":"Briggs","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hec.985","article-title":"Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra","volume":"14","author":"Claxton","year":"2005","journal-title":"Health Econ"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0160","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","article-title":"\u00bfQu\u00e9 es una tecnolog\u00eda sanitaria eficiente en Espa\u00f1a?","volume":"16","author":"Sacrist\u00e1n","year":"2002","journal-title":"Gac Sanit"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0165","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1576-9887(10)70021-2","article-title":"Coste-utilidad de la incorporaci\u00f3n de las nuevas vacunas antineumoc\u00f3cicas conjugadas al programa de vacunaci\u00f3n de la Comunidad de Madrid. Impacto sobre la enfermedad neumoc\u00f3cica invasora","volume":"11","author":"Picazo","year":"2010","journal-title":"Vacunas"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0170","unstructured":"European Medicines Agency (EMA). Committee for medicinal products for human use. Guideline on clinical evaluation of new vaccines (EMEA\/CHMP\/VWP\/164653\/2005). Disponible en http:\/\/www.emea.europa.eu\/pdfs\/human\/vwp\/16465305enfin.pdf"},{"key":"10.1016\/j.gaceta.2011.03.006_bib0175","unstructured":"Clinicaltrial.gov [Internet]. Bethesda: U.S. National Library of Medicine. Disponible en: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00466947?term=NCT+00466947&rank=1."},{"key":"10.1016\/j.gaceta.2011.03.006_bib0180","doi-asserted-by":"crossref","first-page":"A426","DOI":"10.1016\/S1098-3015(10)75105-6","article-title":"Modeling the outcomes of vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) in Spain","volume":"12","author":"Mar\u00e8s","year":"2009","journal-title":"Value in Health"}],"container-title":["Gaceta Sanitaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213911111000963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213911111000963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T13:58:38Z","timestamp":1686146318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213911111000963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0213911111000963"],"URL":"https:\/\/doi.org\/10.1016\/j.gaceta.2011.03.006","relation":{},"ISSN":["0213-9111"],"issn-type":[{"value":"0213-9111","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}